Cardiovascular Drugs Practice Questions

Q: Which of the following statements about hydralazine is NOT true?

It causes dilatation of both arteries and veins.. **Explanation:** Hydralazine is a **direct-acting vasodilator** primarily used in the management of hypertensive emergencies (especially in pregnancy) and chronic heart failure (in combination with nitrates). **1. Why Option B is the correct answer (The False Statement):** Hydralazine is a **selective arterial vasodilator**. It acts directly on the smooth muscles of the arterioles but has **minimal to no effect on the venous system** (veins). Because it does not cause venodilation, it does not significantly decrease preload or cause the peripheral venous pooling that leads to orthostatic hypotension. **2. Analysis of Incorrect Options (True Statements):** * **Option A:** Hydralazine causes **direct relaxation** of vascular smooth muscle, likely by interfering with calcium metabolism and increasing local nitric oxide levels. * **Option C:** Since hydralazine does not affect the venous capacitance vessels, **postural (orthostatic) hypotension is rare**, unlike with alpha-blockers or nitrates. * **Option D:** Arteriolar dilation triggers a **baroreceptor-mediated sympathetic surge**. This leads to reflex tachycardia and an **increase in plasma renin activity**, causing sodium and water retention. This is why it is often co-administered with a beta-blocker and a diuretic. **High-Yield Clinical Pearls for NEET-PG:** * **Drug-Induced Lupus Erythematosus (DILE):** A classic side effect of hydralazine, especially in **slow acetylators**. It is associated with **Anti-Histone Antibodies**. * **Drug of Choice:** It is a preferred parenteral drug for **Hypertension in Pregnancy** (Preeclampsia/Eclampsia). * **Combination Therapy:** When combined with **Isosorbide Dinitrate (BiDil)**, it has been shown to improve mortality in African-American patients with heart failure.

Q: Which of the following drugs is NOT used in the management of chronic heart failure?

Isosorbide dinitrate. **Explanation:** The management of Chronic Heart Failure (CHF) focuses on drugs that provide a **mortality benefit** by inhibiting maladaptive neurohormonal remodeling (the RAAS and sympathetic nervous system). **Why Isosorbide Dinitrate is the correct answer:** While nitrates are potent vasodilators, **Isosorbide dinitrate (ISDN) alone** is typically used for symptomatic relief in acute heart failure or angina. In chronic heart failure, it does not provide a significant survival benefit when used as monotherapy. It is only recommended for chronic management when **combined with Hydralazine** (BiDil), specifically in patients of African-American descent or those intolerant to ACE inhibitors/ARBs [1, 2]. **Analysis of Incorrect Options:** * **Lisinopril (ACE Inhibitor):** These are first-line agents in CHF. they decrease preload and afterload and, most importantly, prevent cardiac remodeling, significantly reducing mortality [1]. * **Spironolactone (Mineralocorticoid Receptor Antagonist):** It blocks the effects of aldosterone. Clinical trials (like RALES) have proven it reduces mortality and hospitalization in patients with NYHA Class II-IV heart failure [1]. * **Losartan (ARB):** Used as an alternative to ACE inhibitors (especially if the patient develops a cough). Like ACE inhibitors, ARBs provide a mortality benefit by blocking the RAAS pathway [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs improving survival in CHF:** ACE inhibitors, ARBs, Beta-blockers (Carvedilol, Metoprolol succinate, Bisoprolol), Spironolactone, and ARNIs (Sacubitril/Valsartan). * **Drugs only for symptomatic relief (No mortality benefit):** Digoxin, Loop diuretics (Furosemide), and Ionotropes (Dopamine/Dobutamine) [1]. * **Hydralazine + ISDN:** The only nitrate combination proven to reduce mortality in specific populations (African-Americans) [1, 2].

Q: Which of the following is a new drug that acts by inhibiting PCSK9?

Alirocumab. **Explanation:** **Alirocumab** is a human monoclonal antibody that acts as a **PCSK9 inhibitor**. **Mechanism of Action:** PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) is an enzyme that binds to LDL receptors (LDL-R) on the surface of hepatocytes and promotes their degradation. By inhibiting PCSK9, Alirocumab increases the number of available LDL receptors on the liver cell surface. This leads to increased clearance of LDL-cholesterol from the blood, significantly lowering plasma LDL levels. It is primarily used in patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional LDL lowering. **Analysis of Incorrect Options:** * **Reslizumab (A):** An interleukin-5 (IL-5) antagonist used as add-on maintenance treatment for severe eosinophilic asthma. * **Brodalumab (B):** An interleukin-17 (IL-17) receptor antagonist used in the treatment of moderate-to-severe plaque psoriasis. * **Ixekizumab (D):** Another IL-17A inhibitor used for plaque psoriasis and psoriatic arthritis. **High-Yield Clinical Pearls for NEET-PG:** * **PCSK9 Inhibitors:** Include **Alirocumab** and **Evolocumab**. They are administered via subcutaneous injection every 2–4 weeks. * **Efficacy:** They can reduce LDL-C by up to 50–70%, even in patients already on maximal statin therapy. * **Inclisiran:** A newer agent (small interfering RNA or siRNA) that also targets PCSK9 synthesis in the liver but has a longer duration of action (dosed every 6 months). * **Adverse Effects:** Generally well-tolerated; most common side effects include injection site reactions and nasopharyngitis.

Q: Sildenafil (Viagra) produces its physiological effects by blocking the enzyme that hydrolyzes the second messenger by which nitric oxide produces its physiological effects. What is this second messenger?

Cyclic GMP. **Explanation:** **Mechanism of Action:** Nitric Oxide (NO) is a potent vasodilator released from vascular endothelial cells. It activates the enzyme **Guanylate Cyclase**, which converts GTP into **Cyclic GMP (cGMP)**. cGMP acts as the **second messenger** that triggers protein kinase G, leading to smooth muscle relaxation and increased blood flow (vasodilation). In the corpus cavernosum, this process results in penile erection. Sildenafil is a selective inhibitor of **Phosphodiesterase-5 (PDE-5)**, the enzyme responsible for the hydrolysis (breakdown) of cGMP. By blocking PDE-5, Sildenafil prevents the degradation of cGMP, prolonging its vasodilatory effects. **Analysis of Incorrect Options:** * **A. Bradykinin:** This is a potent vasodilator peptide, not a second messenger. It works by stimulating the release of NO and prostacyclin. * **C. Protein kinase A:** This is the downstream effector for the **cAMP** pathway (e.g., stimulated by Beta-agonists), not the cGMP pathway. * **D. Endothelin:** This is a potent endogenous **vasoconstrictor** peptide, acting in opposition to the effects of Nitric Oxide. **High-Yield NEET-PG Pearls:** * **Drug Interaction:** Sildenafil is strictly contraindicated with **Nitrates** (e.g., Nitroglycerin) because both increase cGMP through different mechanisms, leading to synergistic peripheral vasodilation and life-threatening hypotension. * **Other PDE-5 Inhibitors:** Tadalafil (longer half-life, "the weekend pill") and Vardenafil. * **Other Indications:** PDE-5 inhibitors are also used in the management of **Pulmonary Arterial Hypertension (PAH)**. * **Side Effect:** "Blue vision" (cyanopsia) occurs due to weak inhibition of PDE-6 in the retina.

Q: What is the most common side effect of dihydropyridine calcium channel blockers?

Headache. **Explanation:** Dihydropyridine (DHP) Calcium Channel Blockers (CCBs), such as **Amlodipine** and **Nifedipine**, act primarily by inhibiting L-type calcium channels in the vascular smooth muscle. This leads to potent **peripheral vasodilation**. **1. Why Headache is the correct answer:** The primary mechanism of DHP-CCBs is the relaxation of arterial smooth muscle. This causes significant vasodilation of the meningeal and cerebral vessels. The resulting increase in intracranial blood flow and stretching of vessel walls triggers sensory nerves, leading to **vasodilatory headaches**. This is the most frequently reported side effect, especially during the initiation of therapy. Other common side effects due to this same mechanism include **peripheral edema** (due to precapillary dilation) and **flushing**. **2. Why the other options are incorrect:** * **B. Constipation:** This is a classic side effect of **Verapamil** (a non-dihydropyridine CCB). Verapamil inhibits calcium channels in the gastrointestinal smooth muscle, leading to decreased motility. It is rarely seen with DHPs. * **C. Diarrhoea:** This is not a characteristic side effect of CCBs. In fact, CCBs are more likely to cause decreased bowel motility. * **D. Muscle cramps:** While occasionally reported, these are not a "most common" or "classic" side effect compared to the vascular symptoms of DHPs. **High-Yield Clinical Pearls for NEET-PG:** * **Peripheral Edema:** A highly characteristic side effect of Amlodipine; it is **not** due to fluid overload but due to increased capillary hydrostatic pressure (pre-capillary dilation). * **Reflex Tachycardia:** Common with short-acting DHPs (like Nifedipine) due to rapid vasodilation triggering the baroreceptor reflex. * **Gingival Hyperplasia:** A shared side effect of CCBs (especially Nifedipine), Phenytoin, and Cyclosporine.

Q: Lipid-lowering agents, statins, act in all the following ways except:

Decreased LDL receptors. ### Explanation Statins (HMG-CoA reductase inhibitors) are the first-line agents for hypercholesterolemia. The core mechanism involves the competitive inhibition of the rate-limiting enzyme in cholesterol biosynthesis. **Why "Decreased LDL receptors" is the correct answer (the exception):** Statins actually **increase** the expression of LDL receptors. When statins inhibit hepatic cholesterol synthesis, the intracellular pool of cholesterol drops. To compensate, the liver upregulates the synthesis of LDL receptors on the hepatocyte surface. These receptors then clear more LDL and VLDL remnants from the circulation, leading to a significant drop in plasma LDL levels. Therefore, saying statins *decrease* these receptors is physiologically incorrect. **Analysis of Incorrect Options:** * **A & C (Inhibiting HMG CoA reductase / Decreased hepatic synthesis):** These are the primary actions of statins. By mimicking the substrate HMG-CoA, they block the conversion of HMG-CoA to mevalonate, directly halting endogenous cholesterol production. * **D (Decreasing VLDL):** Since VLDL is a precursor to LDL and requires cholesterol for its assembly, the reduction in hepatic cholesterol availability leads to a secondary decrease in VLDL secretion. **High-Yield Clinical Pearls for NEET-PG:** * **Pleiotropic Effects:** Statins have "extra" benefits beyond lipid lowering, including plaque stabilization, anti-inflammatory properties, and improved endothelial function. * **Timing:** Most statins (except Atorvastatin and Rosuvastatin) should be taken at **bedtime** because peak cholesterol synthesis occurs during the night. * **Side Effects:** Monitor for **myopathy** (elevated CPK) and hepatotoxicity. Risk increases when combined with Fibrates or Cytochrome P450 inhibitors. * **Contraindication:** Statins are strictly **Teratogenic** (Category X).

Q: Which of the following is FALSE regarding quinidine?

Used in hypertension. **Explanation:** Quinidine is a **Class IA antiarrhythmic** drug derived from the cinchona bark. The correct answer is **B** because Quinidine is not used in the treatment of hypertension; in fact, it can cause hypotension as a side effect due to its alpha-adrenergic blocking properties. **Analysis of Options:** * **A. Increases effective refractory period (ERP):** This is **TRUE**. As a Class IA agent, Quinidine blocks fast sodium channels and inhibits outward potassium channels. Blocking potassium channels prolongs the action potential duration (APD) and the ERP. * **B. Used in hypertension:** This is **FALSE**. It has no role in managing high blood pressure. Its primary use is maintaining sinus rhythm in patients with atrial flutter or fibrillation. * **C. Causes paradoxical tachycardia:** This is **TRUE**. Quinidine has significant **antimuscarinic (atropine-like) effects**. In atrial flutter, it can enhance AV conduction, leading to a dangerous increase in ventricular rate (paradoxical tachycardia). To prevent this, it is usually co-administered with AV nodal blockers like Digoxin or Beta-blockers. * **D. Cinchonism is seen:** This is **TRUE**. Cinchonism is a classic adverse effect profile characterized by tinnitus, blurred vision, dizziness, and headache. **High-Yield Clinical Pearls for NEET-PG:** * **ECG Changes:** Quinidine causes prolongation of the **QT interval**. * **Torsades de Pointes:** Due to QT prolongation, it can trigger this life-threatening polymorphic ventricular tachycardia. * **Drug Interaction:** Quinidine increases plasma levels of **Digoxin** by displacing it from tissue binding sites and reducing its renal clearance. * **Hematology:** It is a well-known cause of immune-mediated thrombocytopenia.

Question 1

Which of the following statements about hydralazine is NOT true?

Accepted Answer

It causes dilatation of both arteries and veins.

Answer

It causes direct relaxation of blood vessels.

Answer

Postural hypotension is not a common problem.

Answer

It increases plasma renin activity.

Question 2

Which of the following drugs is NOT used in the management of chronic heart failure?

Accepted Answer

Isosorbide dinitrate

Answer

Lisinopril

Answer

Spironolactone

Answer

Losartan

Question 3

Which of the following is a new drug that acts by inhibiting PCSK9?

Accepted Answer

Alirocumab

Answer

Reslizumab

Answer

Brodalumab

Answer

Ixekizumab

Question 4

Which of the following calcium channel blockers is indicated for increased intracranial tension?

Accepted Answer

Nimodipine

Answer

Nicardipine

Answer

Clevidipine

Answer

Nitrendipine

Question 5

A 42-year-old woman with a 20-year history of Type II diabetes has hypertension with a BP in the 150/94 mmHg range and mild proteinuria on urinalysis. Which drug would be the best to treat the hypertension in this individual?

Accepted Answer

Enalapril

Answer

Hydrochlorothiazide

Answer

Propranolol

Answer

Nifedipine

Question 6

Sildenafil (Viagra) produces its physiological effects by blocking the enzyme that hydrolyzes the second messenger by which nitric oxide produces its physiological effects. What is this second messenger?

Accepted Answer

Cyclic GMP

Answer

Bradykinin

Answer

Protein kinase A

Answer

Endothelin

Question 7

What is the most common side effect of dihydropyridine calcium channel blockers?

Accepted Answer

Headache

Answer

Constipation

Answer

Diarrhoea

Answer

Muscle cramps

Question 8

Which of the following drugs can cause coronary steal phenomenon?

Accepted Answer

Hydralazine

Answer

Glyceryl trinitrate

Answer

Disopyramide

Answer

Diltiazem

Question 9

Lipid-lowering agents, statins, act in all the following ways except:

Accepted Answer

Decreased LDL receptors

Answer

Decreased hepatic cholesterol synthesis

Answer

Inhibiting HMG CoA reductase

Answer

Decreasing VLDL

Question 10

Which of the following is FALSE regarding quinidine?

Accepted Answer

Used in hypertension

Answer

It increases effective refractory period

Answer

Causes paradoxical tachycardia

Answer

Cinchonism is seen

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?